Impax Laboratories Inc. (IPXL) announced Thursday morning that the FDA has approved RYTARY for the treatment of Parkinson's disease.
Impax Laboratories gapped open sharply higher Thursday and posted gains in early trade, before settling into a range. The stock closed up by 3.61 at $34.60 on above average volume. Impax Laboratories climbed past the upper end of a month and a half long trading range and set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.